SCHEMBL3014203

SCHEMBL3014203

COc1cc(-c2csc(N3CCC(S(=O)(=O)c4c(F)c(Br)cc(F)c4Br)CC3)n2)cc(OC)c1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.51
ALDH1A1 P00352 2/20 0.51
GAA P10253 1/20 0.51
SMN1; SMN2 Q16637 6/20 0.39
MAPT P10636 5/20 0.39
RAB9A P51151 5/20 0.39
NPC1 O15118 4/20 0.39
AR P10275 3/20 0.38
HTR6 P50406 1/20 0.38
RECQL P46063 2/20 0.37
USP2 O75604 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NTSR1 P30989 1/20 0.36
LMNA P02545 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NEK2 P51955 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008133 0.88 MAPK1 (0.58) MAPK1ALDH1A1GAASMN1; SMN2MAPT
SCHEMBL3010981 0.87 SMN1; SMN2 (0.52) MAPK1ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL3015244 0.87 SMN1; SMN2 (0.41) MAPK1ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL3013008 0.86 MAPK1 (0.52) MAPK1ALDH1A1GAASMN1; SMN2MAPT
SCHEMBL3015794 0.86 HTR6 (0.36) MAPK1ALDH1A1GAAMAPTAR
SCHEMBL3011470 0.86 AR (0.47) MAPK1SMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3018754 0.85 MAPK1 (0.55) MAPK1ALDH1A1GAASMN1; SMN2MAPT
SCHEMBL3020217 0.85 MAPT (0.55) MAPK1ALDH1A1GAASMN1; SMN2MAPT
SCHEMBL3015293 0.84 SMN1; SMN2 (0.50) MAPK1ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL3016675 0.84 MEN1 (0.47) MAPK1SMN1; SMN2MAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPK1 2767/4885ALDH1A1 3510/4885GAA 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.